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Abstract 
We recently established a novel drug delivery system (DDS) using oligomannose-coated liposomes (OMLs) taken up by 
peritoneal phagocytic cells to carry anti-cancer drugs to milky spots known as a preferential metastatic site of gastric cancers
(Ikehara et al. 2006. Cancer Res. 66: 8740-8748). In the present study, we applied this intraperitoneal DDS for systemic tumor 
immunotherapy employing ovalbumin (OVA) as a model antigen. The phagocytic cells ingesting the OMLs containing OVA 
(OML-OVA) injected into the peritoneal cavity were predominantly macrophages (MI), as they showed adhesive characteristics 
and expressed F4/80 and CD11b almost exclusively. Peritoneal MI taking up OML-OVA could activate OVA-specific CD8+
(from OT-I: OVA257-264/H-2Kb-specific) and CD4+ (from OT-II: OVA323-339/H-2Ab-specific) T cells much more effectively in 
vitro than those taking up soluble OVA. Furthermore, only the mice immunized with OML-OVA rejected E.G7-OVA (OVA-
transfected EL4) but not EL4. These results indicate that the OMLs can also be used as an effective antigen delivery system for
tumor immunotherapy activating both CD8+ and CD4+ T cell subsets. 
© 2009 Elsevier B.V. 
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1.  Introduction 
Recent advances in tumor immunology enable us to identify tumor antigens recognized by T cells and understand 
the molecular and cellular bases of T cell-mediated anti-tumor responses (1, 2). However, there are several problems 
left for the establishment of effective immunotherapy against solid tumors. Many CD8+ and CD4+ T cells 
recognizing tumor antigens in the context of MHC class I and II, respectively, have been reported, and the former 
are known to be a major effector of the adaptive anti-tumor immune responses (3-5). CD4+ T cells play an important 
role for the expansion and persistence of CD8+ T cells, while some of them are known to function as regulatory cells 
(5-7). Optimal anti-tumor immune responses are therefore considered to require the concomitant activation of both 
CD8+ and CD4+ T cells and the selective activation of CD4+ T cells with helper but not regulatory functions (8). In 
general, endogenous and exogenous antigens are presented as peptides preferentially by MHC class I and II, 
respectively, and most tumor antigen peptides are derived from the proteins expressed endogenously. Novel 
methods to induce effective antigen presentation by MHC class I and II molecules simultaneously are therefore 
needed for the concomitant activation of tumor antigen-specific CD8+ and CD4+ T cells, and many attempts have 
been made for this purpose (2, 3, 8). 
We recently developed a novel drug delivery system (DDS) using oligomannose-coated liposomes (OMLs) (9, 
10) which are effectively taken up by F4/80+ peritoneal cells to carry anti-cancer drugs to milky spots known as a 
preferential metastatic site of gastric and ovarian cancers (9). We demonstrated that this system could control the 
formation of overt metastasis of seeded gastric cancer cells at the extra-nodal lymphoid tissues such as the omentum 
(10-12).
In the present study, we applied this OML-based intraperitoneal DDS for tumor immunotherapy using ovalbumin 
(OVA) as a model antigen, aiming at the concomitant activation of antigen-specific CD8+ and CD4+ T cells. 
Peritoneal macrophages (MI) took up OMLs containing OVA (OML-OVA) and activated both OVA-specific CD8+
and CD4+ T cells effectively in vitro. In addition, OML-OVA immunized mice rejected tumor cells expressing OVA 
but not their parental cells. These results together indicate the potential of our novel OML-based immunization for 
the development of effective tumor immnotherapy. 
2.  Materials and methods 
Mice. Female C57BL/6 (B6) mice at 8-12 weeks of age were obtained Charles River Japan Inc. (Yokohama, 
Japan). T cell receptor (TCR) transgenic mice OT-I (specific for OVA257-264 peptide presented by H-2Kb) (13, 14) 
and OT-II (specific for OVA323-339 peptide presented by H-2Ab) (15) were obtained from the Jackson Laboratory 
(Bar Harbor, ME). All animal experiments were performed under the experimental protocol approved by the Ethics 
Review Committee for Animal Experimentation of Aichi Cancer Center. 
Cell lines. EL4 (16), a B6-derived thymoma cell line, was maintained in RPMI1640 medium (Invitrogen, 
Carlsbad, CA) supplemented with 8% fetal bovine serum, 0.2% L-glutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin, 0.1% HEPES, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, and 50 PM 2-ME 
(complete RPMI). E.G7-OVA (EL4 transfected with OVA gene) (17) was obtained from ATCC (Manassas, VA) and 
maintained in complete RPMI supplemented with 400 µg/ml G418 (Wako, Osaka, Japan) in a humidified 5% CO2
incubator at 37°C. 
Man3-DPPE and liposome preparation. Dipalmitoylphosphatidylcholine (DPPC), cholesterol, and 
dipalmitoylphosphatidylethanolamine (DPPE) were purchased from Sigma-Aldrich (St. Louis, MO). Mannotriose 
(Man3: ManD1-6(ManD1-3)Man) was purchased from Funakoshi (Tokyo, Japan). Man3-DPPE was prepared by 
conjugation of the mannotriose with DPPE by reductive amination as described previously (10, 18). The purity of 
Man3-DPPE was confirmed by high-performance thin-layer chromatography (Silica gel 60 HPTLC plate, MERCK, 
Darmstadt, Germany) and time-of-flight mass spectrometry (Auto FLEX, Bruker Daltonics, Bremen, Germany). 
The purified Man3-DPPE was quantified by determination of the phosphate contained. 
OMLs were prepared as described previously (10). Briefly, a chloroform-methanol (2:1, v/v) solution containing 
1.5 µmol of DPPC and 1.5 µmol of cholesterol was placed in a conical flask and dried by rotary evaporation. 
Subsequently, 2 ml ethanol containing 0.15 µmol of Man3-DPPE was added to the flask and evaporated to prepare a 
lipid film containing neoglycolipids. Procedures for protein-encasing into OMLs were performed as described 
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previously (10). The multilamellar vesicles were generated with either 200 µl of FITC-labeled or non-labeled OVA 
(5.0 mg/ml, Sigma-Aldrich) in the dried lipid film by intense vortex dispersion. The multilamellar vesicles were 
extruded 10 times through polycarbonate membranes of 1 µm pore (Nucleopore, Pleasanton, CA). OMLs entrapping 
proteins were separated from free proteins by four successive rounds of washing in PBS with centrifugation 
(20,000 x g, 30 min) at 4qC. The amounts of entrapped proteins were measured using a modified Lowry protein 
assay reagent (Pierce Biotechnology, Inc., Rockford, IL) in the presence of 0.3% (w/v) sodium dodecyl sulfate using 
bovine serum albumin as a standard. 
Flow cytometry. One hour after intraperitoneal injection of OMLs containing FITC-OVA, peritoneal cells were 
recovered from B6 mice with 5 ml ice cold PBS. Peritoneal cells were incubated on ice for 30 min with PE-labeled 
antibodies after blocking with mouse Fc Blocker (BD Biosciences, San Jose, CA) and then analysed on a 
FACSCalibur (BD Biosciences). The following monoclonal antibodies used in this study were purchased or kindly 
provided: anti-F4/80 (A3-1, Serotec Ltd., Oxford, UK), anti-MHC class II (M5/114.15.2, e-Bioscience, Boston, 
MA), anti-CD11b (M1/70.15, Caltag Laboratories, Burlingame, CA), anti-CD3H (145-2C11, BD Biosciences), anti-
CD19 (1D3, BD Biosciences), and anti-H-2KbDb (20-8-4S, Dr. E. Nakayama, Okayama University). 
In vitro activation of OVA-specific T cells. One hour after injection of either OML-OVA or soluble OVA into 
the peritoneal cavity of B6 mice, peritoneal cells were recovered with 5 ml ice cold PBS. The suspended peritoneal 
cells in complete RPMI were seeded into a 96-well culture plate (5 x 105 cells in each well) and incubated overnight 
at 37qC in a humidified 5% CO2 incubator. On the next day, non-adherent cells were washed out with complete 
RPMI, and the adherent cells preferentially consisting of MI were co-cultured with 5 x 105 cells of either CD8+ or 
CD4+ T cells from the spleen of OT-I and OT-II mice, respectively. CD8+ and CD4+ T cells were prepared with the 
isolation kits for corresponding subsets (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). The supernatants 
were collected at 24 h and assayed for IFN-J production with Mouse IFN-JELISA kit (Pierce). 
In vivo tumor growth. B6 mice were immunized three times biweekly by peritoneal injection of 1 Pg OML-
OVA. One week after the final immunization, tumor cells were injected subcutaneously into the backs of mice, and 
the survival time was observed. 
3.  Results 
OMLs are taken up preferentially by peritoneal MI. We showed that OMLs are incorporated very effectively by 
peritoneal cells expressing F4/80 and that the OML-ingesting cells are very useful drug delivery vehicles for tumor 
chemotherapy (9, 10). To verify whether the OMLs are applicable also for tumor immunotherapy, we first analyzed 
the F4/80+ peritoneal cells in detail. FITC-labeled OVA was encased in OML and injected into the peritoneal cavity 
of B6 mice. One hour after the OML injection, peritoneal cells were collected and analyzed. As shown in Figure 1, 
peritoneal cells were divided into three groups based on the incorporation of OMLs. Most OVAhigh cells expressed 
F4/80 and CD11b but not CD3 and CD19, and this population could be removed by plastic adherence. These 
observations together suggest that OVAhigh population preferentially consists of MI. The peritoneal cells with lower 
OML uptake (OVAlow) did not express F4/80, and nearly 2/3 of them were considered to be B cells because of their 
CD19 expression. 
Figure 1. Surface phenotype of peritoneal cells from OML-injected mice. One hour after the injection of OMLs containing FITC-labeled 
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Peritoneal MI ingesting OML-OVA activate both CD8+ and CD4+ T cells in vitro in an antigen-specific 
manner. We next analyzed the antigen-presenting capacity of the peritoneal MI ingesting OML-OVA. CD8+ T cells 
from OT-I (OVA257-264/H-2Kb-specific) and CD4+ T cells from OT-II (OVA323-339/H-2Ab-specific) were used as 
responder cells. When these T cells were co-cultured with peritoneal MI from the mice intraperitoneally injected 
with OML-OVA, both CD8+ and CD4+ T cells produced large amounts of IFN-J (Figure 2). Although MI from the 
mice injected with soluble OVA also stimulated both CD8+ and CD4+ T cells, much higher amounts of OVA were 
needed compared to those from the mice injected with OML-OVA. We also found that cytotoxic T lymphocytes 
(CTL) against E.G7-OVA can be effectively induced in B6 mice immunized with OML-OVA (data not shown). 
Figure 2. Peritoneal MI ingesting OML-OVA activate OVA-specific CD8+ and CD4+ T cells much more 
effectively than those ingesting soluble OVA. One hour after intraperitoneal injection of antigens, peritoneal cells 
were prepared from the immunized mice, and MI were enriched by plastic adherence. CD8+ and CD4+ T cells were 
purified from the spleen of OT-I and OT-II, respectively, and co-cultured with peritoneal MI for 24 h. The 
supernatants were then collected and assayed for IFN-J production by ELISA. Peritoneal MI obtained from naïve 
mice were also used as a control. 
OML-mediated immunization induces antigen-specific anti-tumor immunity in vivo. We finally examined 
whether intraperitoneal immunization with OMLs also induces antigen-specific anti-tumor immunity in vivo. Mice 
were immunized intraperitoneally with OML-OVA and then challenged subcutaneously with E.G7-OVA or EL4. As 
shown in Figure 3, only the immunized mice survived for more than 70 days when challenged with E.G7-OVA, 
while naïve mice died within 55 days. All the mice including those immunized with OML-OVA died within 30 days 
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together show that OML-mediated immunization can induce systemic immune response robust enough to protect 
mice from tumor challenge in an antigen-specific manner. 
Figure 3. OML-mediated immunization induces antigen-specific anti-tumor immunity in vivo. B6 mice were 
immunized three times biweekly by peritoneal injection of 1 Pg OML-OVA. One week after the last challenge, 
OML-OVA immunized (circles) and naïve (squares) mice were challenged subcutaneously with E.G7-OVA (closed 
symbols) or EL4 (open symbols). 
4. Discussion 
In this study, we demonstrated that our novel OML-based DDS targeted to peritoneal MI can also be used for the 
induction of systemic immune responses. After ingesting OML-OVA, MI migrate to extra-nodal lymphoid tissues 
in abdominal cavity and present OVA-derived peptides in the context of both MHC class I and II molecules. Only 
the mice immunized with OML-OVA rejected the challenge of E.G7-OVA but not EL4. These results together 
indicate that the OMLs can be used as an effective antigen delivery system for tumor immunotherapy activating 
both CD8+ and CD4+ T cell subsets as well as a DDS for tumor chemotherapy (Figure 4). 
OML-OVA / E.G7-OVA
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Figure 4. Applications of OMLs for tumor treatment. 
OMLs are very useful not only for the promotion of antigen uptake by antigen-presenting cells but also for the 
enhancement of antigen processing of encased antigens. In general, endogenous and exogenous antigens are 
presented preferentially by MHC class I and II, respectively. OML-encased antigens, however, were effectively 
directed to both pathways, even when added exogenously. This advantage of OML-mediated immunization will 
hopefully facilitate the simultaneous activation of tumor-specific CD4+ and CD8+ T cells as shown in this study with 
OVA. In addition, intraperitoneal uptake of OMLs also induces MI maturation with up-regulation of MHC class II 
and co-stimulatory molecules and IL-12 production, resulting in an effective induction of antigen-specific type 1 
helper T cell (Th1) responses (19, 20). Indeed, OT-I and OT-II T cells stimulated with MI ingesting OML-OVA 
produced IFN-J but not IL-4 or IL-10 (Figure 2 and unpublished observation). 
Recently, we have shown that OMLs activate phosphatidylinositol 3-kinase/Akt pathway through 
phosphorylation of Src family kinases to induce the activation of mitogen-activated protein kinases in MI-like 
J774A.1 cells (21). We have also shown that peritoneal MI uptake OMLs through a cooperation of specific ICAM-3 
garbbing nonintegrin-related 1 (SIGNR1) and complement receptor type 3 (CR3) (22, 23). Thus, SIGNR1 (maybe 
together with CR3) may associate with nonreceptor-type tyrosine kinases in lipid rafts during OML recognition, and 
complexes of these molecules facilitate subsequent OML uptake and signal transduction to induce an OML-induced 
Th1 response. 
In order to apply our OMLs in clinical study, the best administration routes should be determined to pursue 
repetitive vaccination while avoiding possible side effects. As generally acknowledged, intraperitoneal 
administration is accompanied with a high risk of side effects such as catheter-related complications and abdominal 
pain. Indeed, it is difficult to complete repetitive intraperitoneal chemotherapy in some cases due to such side effects 
(24). In this connection, we have already obtained effective in vivo anti-tumor responses by subcutaneous injection 
of OMLs containing tumor antigens (25). However, side effects induced by subcutaneous injection of OMLs should 
be further investigated to assure their safe clinical application. 
In the previous study, we reported that the formation of peritoneal metastasis of seeded gastric cancer cells in 
milky spots can be controlled with OMLs containing anti-cancer drugs (10). In the present study, we have further 
extended the possibility of OMLs for the immunotherapy of systemic metastasis and existing tumor cells aside from 
milky spots. Oligomannose-coating of liposomes showed the best uptake efficiency by peritoneal MI among the 
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molecules. However, the effects for immune responses induced by other neoglycolipids have not been studied at all 
so far. We have a great interest in this issue and are seeking the materials with immunoregulatory properties. If such 
materials would be found, our neoglycolipid-coated liposome technology might be further applicable for antigen-
specific regulation of autoimmune diseases and allergy. 
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